Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvER-ILD: Rituximab + MMF vs MMF Alone in ILD
NCT02990286Phase 3Completed
- Sponsor
- University Hospital Tours
- Start
- Jan 2017
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in interstitial lung disease (ILD) comparing Rituximab with Mycophenolate Mofetil with Placebo of rituximab with Mycophenolate Mofetil (2 arms). Primary endpoint: Change in Forced Vital Capacity in % of predicted at 6 months. Started Jan 2017; status: completed.
02
Drugs
rituximab
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT02990286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02990286.